Smith & Nephew Regulatory News (SN.)

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Smith & Nephew plc ordinary shares of USD 0.20 each

Identification code

ISIN: GB0009223206

Nature of the transaction

Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2021 interim dividend payment on 27 October 2021.

Date of Transaction

2021 - 10 - 27

Place of Transaction

London Stock Exchange (XLON)

Name

(Position)

Director / PDMR

Price

Volume

Aggregated information

Total Ordinary Share Holding following the transaction *

Total Ordinary Share Holding as a % of the Company's ISC following the transaction *

Bradley Cannon

(President Sports Medicine & ENT)

PDMR

£13.06288

1.04868

N/A Single Transaction

77,922.43852 (including 2,414.63870 in ADS')

0.00880%

Phil Cowdy

(Chief Business Development & Corporate Affairs Officer)

PDMR

£13.06288

83.67835

N/A Single Transaction

45,493.96621

0.00514%

Myra Eskes

(President APAC Region)

PDMR

£13.06288

23.35315

N/A Single Transaction

2,928.68131

0.00033%

Simon Fraser

(President Advanced Wound Management)

PDMR

£13.06288

85.03095

N/A Single Transaction

10,663.59428

0.00120%

Skip Kiil

(President Orthopaedics)

PDMR

£13.06288

74.08913

N/A Single Transaction

12,202.12693

0.00138%

Catheryn O'Rourke

(Chief Legal & Compliance Officer)

PDMR

£13.06288

435.47055

N/A Single Transaction

83,240.14924 (including 6,170.31995 in ADS')

0.00940%

Susan Swabey

(Company Secretary)

PDMR

£13.06288

142.14675

N/A Single Transaction

49,558.39347

0.00560%